Sigma, United States
Sigma, United States

Time filter

Source Type

News Article | May 10, 2017
Site: co.newswire.com

BudTrader.com announced today via a blog post that they have hired former weedmaps.com CTO Grant Koeneke Online medical marijuana marketplace BudTrader.com announced today via a blog post that they have hired former weedmaps.com CTO Grant Koeneke. Grant comes to BudTrader.com with a background in Strategic and Operational Technology Planning and Development and is one of the leading experts in Emerging Technologies and Enterprise Database Architecture. "Grant is a genius and a great developer who's also an expert in the online cannabis field,” says BudTrader.com CEO Brad McLaughlin. “He comes to us from Weedmaps, where he created industry-leading technology. We are very excited that Grant is joining our team and accelerate the future of BudTrader.com." BudTrader.com is already the largest online medical marijuana marketplace, and growing quickly. The site now reports upwards of seven million monthly page views, and over 750,000 registered users. The platform allows users in the medical marijuana and legal weed industries to post ads for their products, services, job openings, properties for sale, and more. With new users pouring in, BudTrader.com is focused on building a scalable infrastructure that will allow for fast, exponential growth of their user base that many industry forecasters are predicting. The acquisition of Grant Koeneke from Weedmaps is an indication of the growing clout of BudTrader.com within the online cannabis market. Most recently, a survey of current and former NFL players conducted by BudTrader.com made news in publications like High Times Magazine by revealing potentially serious issues with opiate painkiller use in the NFL, and well as the players’ desire for allowed use of medical marijuana as a pain management alternative. Currently, the NFL has harsh punishments in place for players who test positive for marijuana use, even in states where marijuana is medically or recreationally legal. In addition to his experience as CTO at Weedmaps and his new position with BudTrader.com, Grant Koeneke has served as CTO for Klique Inc., a popular location-based networking app as well as worked for Creative Artists Agency as Director of Engineering.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Certified Patent Valuation Analyst Curriculum Training Sessions" conference to their offering. The Certified Patent Valuation Analyst (CPVA) is a unique designation which indicates that you are one of those rare individuals that has attained a high degree of proficiency in the process of valuing patents and emerging technologies. This designation may help you advance in your career as an intellectual property manager, licensing executive, business development executive, patent agent, or patent attorney. If you are an accountant or valuation professional, the CPVA designation may help you win more clients and grow your business. After receiving the required course credits and passing the exam, you may use the CPVA designation after your name. You must be a member in good standing of The Business Development Academy to continue to use the CPVA designation. As a CPVA, you will receive all of the benefits of being a member of the Organization. The primary benefit is substantial discounts on all courses and events produced by the Organizers. With courses in the fields of Intellectual Property, Corporate Transactions, Negotiations, Financial Modeling and Projections, Strategic Decision Making, Strategic Planning, Business Valuation and more, you will find plenty of courses that will keep you at the top of your profession. In addition, you may arrange to have your name appear on the CPVA site indicating that you have achieved the CPVA designation. You will be eligible to use the Patent Valuation Gauntlet (PVG) stamp on your valuations. For the live sessions, the Valuation of Emerging Technologies course runs on the first of the two days of live training. The Negotiating License Agreements for Maximum Returns and the Calculating Damages Resulting from Patent Infringement courses are run - for 3.5 hours each - on the second day of live training. The Advanced Patent Valuation course is delivered via webinar. For more information about this conference visit http://www.researchandmarkets.com/research/w2dzqj/certified_patent


News Article | May 9, 2017
Site: www.cnet.com

Everybody has a price. Apparently, that also extends to the price people would pay to add self-driving capabilities to their cars. According to a new study from the journal "Transportation Research Part C: Emerging Technologies," people are willing to pay about $3,500 for partial vehicle automation, and about $4,900 for full autonomy. The study defined partial autonomy as being similar to today's advanced driver-assistance systems such as automatic emergency braking. The study pulled data from a panel of 1,260 individuals who answered survey questions related to the vehicle purchase process. While that might seem like a small number, the group running the study managed to scoop up a representative cross-section of the US population. While that might make it sound like everyone agreed on a price, the study actually produced some incredibly diverse answers. Some respondents are entirely unwilling to pay more money for autonomous cars, whereas households with a greater knowledge of the technology might be willing to shell out more than $10,000 for full autonomy. The study admits that, given the relative newness of autonomous-vehicle technology, a lack of understanding on the subject might be contributing to some of these responses. Limited choice in the survey might also contribute to the variation of answers across respondents. No study is perfect, obviously. However, the group running the study believes some of that heterogeneity will fall by the wayside as the technology matures and consumers learn more about autonomous technology. Thankfully, the buyers who aren't willing to pay anything more for autonomy won't have to wait too long for that to be commonplace. Automakers are finally beginning to offer its partially-autonomy systems as standard equipment, ahead of a 2022 mandate to have autonomous emergency braking installed on every new car. And it's not just expensive models that include it as standard -- Toyota is set to outfit nearly every model and trim with autonomous emergency braking within the next year or so.


Dublin, May 08, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market Analysis & Forecast 2017-2023 (Focus on Biomarker Test Type, Application & Market Trends)" report to their offering. This report is focused on emerging cancer diagnostics market specifically on biomarker tumor test. The market growth is propelled due to factors such as: increasing number of cancer cases, technological innovation and advancements, increasing awareness among people, and medicare & reimbursement policies, among others. This study includes an overview and analysis of the emerging cancer diagnostics market, by test type, applications, and geography, allowing the research to develop a comprehensive outlook of the market. The market report presents a detailed and analytical study of the entire market and provides a comprehensive insight into various forms of developments, trends and key participants. The type of cancer, their incidence and prevalence rate has been discussed in the report. While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, associations, and regulatory bodies, and their involvement in the emerging cancer diagnostics market. The answers to the following key questions can be found in the report: - What are the major drivers, challenges and opportunities of the tumor biomarker test market and their use cases? - How is the tumor biomarker test market evolving? - What are the market shares of the leading segments of the tumor biomarker test market in 2015? - How will each test of the tumor biomarker test grow over the forecast period and how much revenue will these account for in 2023? - How will the market shares of the leading national markets change by 2023 and which country will lead the market in 2023? - How the industry will evolve during the forecast period between 2017 and 2023? - What are the key developmental strategies implemented in different applications across all regions? - How will the key market players leverage on key developments such as mergers & acquisitions, partnerships, and product launches among others? - Which geographical region will lead the global tumor biomarker test market by the end of the forecast period? - Who are the key players in the tumor biomarker test market? - What are different application in this market and how are they categorized? - What are the market trends and key developments in different geographical regions? - What are all market available cancer biomarker test? - What is the current market size and future projection for emerging cancer technologies in the major countries? - What are the key sources of information about emerging cancer technologies? - What is the incidence rate of major cancer type? Key Topics Covered: Executive Summary 1 The Research Scope and Methodology 2 Introduction to Global Emerging Cancer Diagnostics Market 2.1 Overview 2.2 Analysis of Lifestyle Factors 2.2.1 Obesity/Weight 2.2.2 Physical Activity 2.2.3 Food Habits 2.2.4 Alcohol & Cancer 2.2.4.1 Countries with Highest Consumption of Alcoholic Drinks 2.2.5 Salt Consumption 2.2.6 Breastfeeding 2.3 High and Low Developed Countries 2.3.1 Men 2.3.2 Women 2.4 Data for Cancer Frequency by Country 2.4.1 Men 2.4.2 Women 2.5 Worldwide Cancer Data 2.5.1 Men 2.5.2 Women 3 Market Dynamics 3.1 Market Drivers 3.1.1 Increase in Prevalence Rate of Cancer 3.1.2 Increase in Sedentary Lifestyles 3.1.3 Robust Technological Advancement 3.1.4 Environmental Hazards 3.1.4.1 Five Primary Categories of Carcinogens are: - 3.1.5 Government Initiatives and Investment 3.2 Market Challenges 3.2.1 High Capital Investment 3.2.2 Dearth of Skilled Professionals 3.2.3 Lack of Awareness 3.3 Market Opportunities 3.3.1 Nanotechnology Applications in Cancer 3.3.2 3D Printing in Cancer Diagnostics 3.3.3 Robotics in Cancer Diagnostics and Treatment 3.3.4 Fluid Biopsy 3.3.5 Real Time Cancer Diagnostic iKnife 4 Competitive Insights 4.1 Key Market Developments & Strategies 4.1.1 Product Launch and Development 4.1.2 Collaborations, Joint Ventures & Partnerships 4.1.3 Business Expansion and Contracts 4.1.4 Patents, Approvals and Certifications 4.1.5 Mergers and Acquisitions 4.1.6 Other Strategies 4.2 Industry Attractiveness 4.3 Global Market Share Analysis 4.3.1 Market Share Analysis 5 Industry Analysis 5.1 Patent Analysis 5.2 Consortiums, Associations and Regulatory Bodies 6 Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market, Analysis and Forecast 6.1 Assumptions & Limitations for Analysis and Forecast 6.2 Market Overview 6.3 Global Emerging Cancer Diagnostics Market by Tumor Biomarker Test 6.3.1 Prostate Specific Antigen Tests 6.3.2 CTC Tests 6.3.3 Alpha-Fetoprotein (AFP) Tests 6.3.4 CA Test 6.3.4.1 CA 19-9 Tests 6.3.4.2 CA 125 Tests 6.3.5 HER2 Tests 6.3.6 BRCA Test 6.3.7 Anaplastic Lymphoma Kinase (ALK) Tests 6.3.8 EGFR Mutation Tests 6.3.9 KRAS Test 6.3.10 Others 6.3.10.1 National Rental Affordability Scheme (NRAS) Testing 6.3.10.2 RET Gene Testing 6.3.10.3 ROS Testing 6.3.10.4 PIK3CA Tests 6.4 Global Emerging Cancer Diagnostics Market by Application 6.4.1 Lung Cancer 6.4.2 Breast Cancer 6.4.3 Colorectal 6.4.4 Prostate Cancer 6.4.5 Blood Cancer 6.4.5.1 Leukaemia 6.4.5.2 Lymphoma 6.4.5.3 Myeloma 6.4.6 Others 6.5 Global Emerging Technologies in Cancer Diagnostics Market by Geography 7 Company Profiles - Abbott Laboratories, Inc - LabCorp Of America Holdings - Luminex Corporation - Myriad Genetics Inc - NanoString Technologies Inc - Neo Genomics Inc - Quest Diagnostics Incorporated - Qiagen, Inc - Roche Holding AG-BR - Siemens Healthineers - Thermo Fisher Scientific - Agilent Technologies - Biotheranostics, Inc - Almac group - GeneNews Limited (formerly ChondroGene Limited) - Rosetta Genomics - Epigenomics - Exact Sciences Corporation - Ignyta,Inc - Interpace Diagnostics - Leica Biosystems - BioTime, Inc - Pathway Genomics - Sysmex Corporation - AstraZeneca - Becton Dickinson & Co - Biocept Inc - Cancer Genetics Inc - Danaher Corporation - Foundation Medicine Inc - Illumina Inc For more information about this report visit http://www.researchandmarkets.com/research/d3w5r6/global_emerging


Dublin, May 08, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market Analysis & Forecast 2017-2023 (Focus on Biomarker Test Type, Application & Market Trends)" report to their offering. This report is focused on emerging cancer diagnostics market specifically on biomarker tumor test. The market growth is propelled due to factors such as: increasing number of cancer cases, technological innovation and advancements, increasing awareness among people, and medicare & reimbursement policies, among others. This study includes an overview and analysis of the emerging cancer diagnostics market, by test type, applications, and geography, allowing the research to develop a comprehensive outlook of the market. The market report presents a detailed and analytical study of the entire market and provides a comprehensive insight into various forms of developments, trends and key participants. The type of cancer, their incidence and prevalence rate has been discussed in the report. While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, associations, and regulatory bodies, and their involvement in the emerging cancer diagnostics market. The answers to the following key questions can be found in the report: - What are the major drivers, challenges and opportunities of the tumor biomarker test market and their use cases? - How is the tumor biomarker test market evolving? - What are the market shares of the leading segments of the tumor biomarker test market in 2015? - How will each test of the tumor biomarker test grow over the forecast period and how much revenue will these account for in 2023? - How will the market shares of the leading national markets change by 2023 and which country will lead the market in 2023? - How the industry will evolve during the forecast period between 2017 and 2023? - What are the key developmental strategies implemented in different applications across all regions? - How will the key market players leverage on key developments such as mergers & acquisitions, partnerships, and product launches among others? - Which geographical region will lead the global tumor biomarker test market by the end of the forecast period? - Who are the key players in the tumor biomarker test market? - What are different application in this market and how are they categorized? - What are the market trends and key developments in different geographical regions? - What are all market available cancer biomarker test? - What is the current market size and future projection for emerging cancer technologies in the major countries? - What are the key sources of information about emerging cancer technologies? - What is the incidence rate of major cancer type? Key Topics Covered: Executive Summary 1 The Research Scope and Methodology 2 Introduction to Global Emerging Cancer Diagnostics Market 2.1 Overview 2.2 Analysis of Lifestyle Factors 2.2.1 Obesity/Weight 2.2.2 Physical Activity 2.2.3 Food Habits 2.2.4 Alcohol & Cancer 2.2.4.1 Countries with Highest Consumption of Alcoholic Drinks 2.2.5 Salt Consumption 2.2.6 Breastfeeding 2.3 High and Low Developed Countries 2.3.1 Men 2.3.2 Women 2.4 Data for Cancer Frequency by Country 2.4.1 Men 2.4.2 Women 2.5 Worldwide Cancer Data 2.5.1 Men 2.5.2 Women 3 Market Dynamics 3.1 Market Drivers 3.1.1 Increase in Prevalence Rate of Cancer 3.1.2 Increase in Sedentary Lifestyles 3.1.3 Robust Technological Advancement 3.1.4 Environmental Hazards 3.1.4.1 Five Primary Categories of Carcinogens are: - 3.1.5 Government Initiatives and Investment 3.2 Market Challenges 3.2.1 High Capital Investment 3.2.2 Dearth of Skilled Professionals 3.2.3 Lack of Awareness 3.3 Market Opportunities 3.3.1 Nanotechnology Applications in Cancer 3.3.2 3D Printing in Cancer Diagnostics 3.3.3 Robotics in Cancer Diagnostics and Treatment 3.3.4 Fluid Biopsy 3.3.5 Real Time Cancer Diagnostic iKnife 4 Competitive Insights 4.1 Key Market Developments & Strategies 4.1.1 Product Launch and Development 4.1.2 Collaborations, Joint Ventures & Partnerships 4.1.3 Business Expansion and Contracts 4.1.4 Patents, Approvals and Certifications 4.1.5 Mergers and Acquisitions 4.1.6 Other Strategies 4.2 Industry Attractiveness 4.3 Global Market Share Analysis 4.3.1 Market Share Analysis 5 Industry Analysis 5.1 Patent Analysis 5.2 Consortiums, Associations and Regulatory Bodies 6 Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market, Analysis and Forecast 6.1 Assumptions & Limitations for Analysis and Forecast 6.2 Market Overview 6.3 Global Emerging Cancer Diagnostics Market by Tumor Biomarker Test 6.3.1 Prostate Specific Antigen Tests 6.3.2 CTC Tests 6.3.3 Alpha-Fetoprotein (AFP) Tests 6.3.4 CA Test 6.3.4.1 CA 19-9 Tests 6.3.4.2 CA 125 Tests 6.3.5 HER2 Tests 6.3.6 BRCA Test 6.3.7 Anaplastic Lymphoma Kinase (ALK) Tests 6.3.8 EGFR Mutation Tests 6.3.9 KRAS Test 6.3.10 Others 6.3.10.1 National Rental Affordability Scheme (NRAS) Testing 6.3.10.2 RET Gene Testing 6.3.10.3 ROS Testing 6.3.10.4 PIK3CA Tests 6.4 Global Emerging Cancer Diagnostics Market by Application 6.4.1 Lung Cancer 6.4.2 Breast Cancer 6.4.3 Colorectal 6.4.4 Prostate Cancer 6.4.5 Blood Cancer 6.4.5.1 Leukaemia 6.4.5.2 Lymphoma 6.4.5.3 Myeloma 6.4.6 Others 6.5 Global Emerging Technologies in Cancer Diagnostics Market by Geography 7 Company Profiles - Abbott Laboratories, Inc - LabCorp Of America Holdings - Luminex Corporation - Myriad Genetics Inc - NanoString Technologies Inc - Neo Genomics Inc - Quest Diagnostics Incorporated - Qiagen, Inc - Roche Holding AG-BR - Siemens Healthineers - Thermo Fisher Scientific - Agilent Technologies - Biotheranostics, Inc - Almac group - GeneNews Limited (formerly ChondroGene Limited) - Rosetta Genomics - Epigenomics - Exact Sciences Corporation - Ignyta,Inc - Interpace Diagnostics - Leica Biosystems - BioTime, Inc - Pathway Genomics - Sysmex Corporation - AstraZeneca - Becton Dickinson & Co - Biocept Inc - Cancer Genetics Inc - Danaher Corporation - Foundation Medicine Inc - Illumina Inc For more information about this report visit http://www.researchandmarkets.com/research/d3w5r6/global_emerging


- Enterprise Ethereum Alliance (EEA), a newly formed enterprise collaboration focused on Ethereum blockchain technology, is pleased to announce the addition of over 86 new companies to its membership with many continuing to onboard and be announced in the upcoming months. Comprised of the most advanced enterprises and startup blockchain innovators, EEA is designed to build, promote, and broadly support Ethereum-based technology best practices, standards, and a reference architecture, EntEth 1.0. The new members of EEA include Access, Adapt Forward, Alchemy Limited, AlphaPoint, Antony Welfare, Aquarius Capital Management, AutoBoard Systems, Axcent LLC, Bancor, BigchainDB, Blk Technologies, Blockchain Hub Limited, BlockCypher, Brian Ray, Broadridge, CareChain, CCA, Clause, Clearmatics Technologies, Clozer Technologies, CoinFund, Coinplug, ConsenLabs, Consensus Base, Couger, CryptoMKT, CYPHA GmbH, Dapps.ai, Datarella, DeliverThat, De Cooperatieve Rabobank U.A, Deloitte, The Depository Trust & Clearing Corporation (DTCC), DigixGlobal, Dinosaur Dog, ElectricChain, Elevondata Labs Inc., Etherisc, Fundacion CTIC Centro Tecnologico, Gem, Global Consent Limited, Global Trade Guardian - LexEcon Consulting Group, Hashed Health, Hijro, Illinois Department of Financial and Professional Regulation, Infosys, InGauge Trading Technologies Inc., Ian Pilon, Infrachain Asbl, Intelligent’er Re’Development, ING, iPaynow, Jiangsu Huaxin Blockchain Research Institute, Kaula, Ledger, Libra, Melonport, Merck KGaA, Darmstadt, Germany, MME, Mitsubishi UFJ Financial Group, Model Communities Association, Musicoin, National Bank of Canada, Noah Perius, Nordic Alliance, NXN, Parkview Ventures, Qingxin Technology, Red Chalk Group, Samsung SDS, San Francisco Stock Exchange, Smart Contract Japan, SmartU Electronics Trading L.L.C, State Street Emerging Technologies Center, Synechron, Taishin Financial Holdings, Taiwan FinTech Association, Tecnalia Research & Innovation, Toyota Research Institute, TraderLynk Ltd, Trust Stamp, UNLP, Utocat, Vanbex Group, Wall Street Blockchain Alliance, and Zerocoin Electric Coin Company. The Enterprise Ethereum Alliance (EEA) was formed earlier this year, seeking to evolve Ethereum so that is can serve as an enterprise-grade technology. EEA’s research and development is focused on privacy, confidentiality, scalability, and security. EEA is also investigating hybrid architectures that span both permissioned and public Ethereum networks as well as industry specific application layer working groups. Julio Faura, chairman of EEA and head of blockchain r&d at Santander expressed, “The enthusiasm around EEA is remarkable. Our new members come from varying industries such as pharma, mobile, banking, automotive, management consulting, and hardware as well as the startup community driving innovation. It’s great to see everyone come together and build the next generation of our economy on Ethereum blockchain solutions.” EEA will collectively develop industry standards and facilitate open source collaboration with its member base and is open to any members of the Ethereum community who wish to participate. This collaborative framework will enable the mass adoption at a depth and breadth otherwise unachievable in individual corporate silos and provide insight to the future of scalability, privacy, and confidentiality of the public Ethereum permissionless network. For additional information about joining EEA, please reach out to [email protected]


News Article | May 18, 2017
Site: www.prweb.com

Zensar Technologies, a leading provider of digital solutions, software and infrastructure services, announced the launch of its Blockchain Enablement Framework. Zensar’s Blockchain enablement framework is designed to address challenges in the context of financial transactions undertaken using digital platforms. It follows a unique business-led consulting approach, bringing Zensar’s expertise in having managed complex transactions for global financial companies to the fore. Enterprises can look forward to enhanced business benefit realization from the ever-increasing digital financial transactions. Additionally, Zensar’s framework incorporates efficiency as well as transparency enabling enterprises to benefit from the simplified approach. Sandeep Kishore, Chief Executive Officer and Managing Director, Zensar Technologies commented, “It is our endeavor to introduce solutions that offer clear Return on Digital™ benefits to global enterprises that are looking for success from their digital transformation initiatives. Our Blockchain framework aims to bring in the business-led consulting approach to a critical area for any financial or non-financial company looking to resolve real business problems. The team is well-versed working with this path-breaking technology led offering to bring about significant outcomes for our customers worldwide.” Gartner Research says, ‘Blockchain is gaining traction because it holds the promise to transform industry operating models. It is also one example of an enabling technology of the platform revolution trend, one of the three trends along with transparently immersive experiences and perceptual smart machine age highlighted in the Gartner Hype Cycle for Emerging Technologies 2016’. * According to Prameela Kalive, EVP and Head, Applications Business Solutions, “Zensar’s Blockchain framework is built with our vast experience in having helped global companies benefit from secure, flexible and effective solutions. We are confident that our customers will derive value from our Blockchain IPs and solution accelerators for both, financial and non-financial applications.” On implementing the Zensar Blockchain Framework, enterprises can achieve measurable returns on their digital investments as follows: *Source: Gartner, Smarter With Gartner, “3 Trends Appear in the Gartner Hype Cycle for Emerging Technologies, 2016”, http://www.gartner.com/smarterwithgartner/3-trends-appear-in-the-gartner-hype-cycle-for-emerging-technologies-2016/ About Zensar (http://www.zensar.com) Zensar is a leading digital solutions and technology services company that specializes in partnering with global organizations across industries on their Digital Transformation journey. A technology partner of choice, backed by a strong track record of innovation; credible investment in Digital solutions; and unwavering commitment to client success, Zensar’ s comprehensive range of digital and technology services and solutions enables its clients achieve new thresholds of business performance. Zensar, with its experience in delivering excellence and superior client satisfaction through myriad technology solutions, is uniquely positioned to help its clients surpass challenges they face running their existing business most efficiently, helping in their legacy transformation, and planning for business expansion and growth through innovative and digital ways. Follow Zensar via: Zensar Blog: http://www.zensar.com/blogs Twitter: https://twitter.com/Zensar LinkedIn: https://www.linkedin.com/company/zensar-technologies Facebook: https://www.facebook.com/Zensar Catch our refreshed new website at: http://www.zensar.com About RPG Enterprises (http://www.rpggroup.com) Mumbai headquartered RPG Enterprises is one of India's largest industrial conglomerates. With over 15 companies in its fold, the group has a strong presence across core business sectors such as Infrastructure, Tyre, IT and Specialty. Established in 1979, RPG Enterprises is one of India’s fastest growing business groups with a turnover in excess of Rs 21,000 crore. Safe Harbor Certain statements in this release concerning our future growth prospects are forward-looking statements which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorised use of our intellectual property and general economic conditions affecting our industry. The Company does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the Company.

Loading Emerging Technologies collaborators
Loading Emerging Technologies collaborators